Fabienne Thomas

List of Publications by Year
in descending order

60	1,600	279487 23	315357 38
papers	citations	h-index	g-index

71	71	71	2275
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Modelâ€Based Quantification of Impact of Genetic Polymorphisms and Coâ€Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer. Clinical Pharmacology and Therapeutics, 2021, 109, 1244-1255.	2.3	19
2	Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients. Cancer Chemotherapy and Pharmacology, 2021, 87, 229-239.	1.1	4
3	Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines. Cancer Chemotherapy and Pharmacology, 2021, 87, 579-583.	1.1	2
4	Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data. Pharmaceuticals, 2021, 14, 162.	1.7	5
5	Multicentric phase II trial of TIâ€CE highâ€dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. Cancer Medicine, 2021, 10, 2250-2258.	1.3	3
6	Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation. Annals of Oncology, 2021, 32, 810-811.	0.6	10
7	DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. Journal of Personalized Medicine, 2021, 11, 792.	1.1	2
8	Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. Pharmaceuticals, 2021, 14, 796.	1.7	13
9	Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the openâ€source R package mapbayr. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1208-1220.	1.3	9
10	Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer. Cancer Research, 2021, 81, 5963-5976.	0.4	10
11	Pharmacogenomics in solid cancers and hematologic malignancies: improving personalized drug prescription. Therapie, 2021, , .	0.6	1
12	Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 907-925.	1.5	3
13	Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma. Cancers, 2020, 12, 3647.	1.7	3
14	Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors. Pharmaceutical Research, 2020, 37, 147.	1.7	2
15	New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine. Cancer Chemotherapy and Pharmacology, 2020, 86, 45-54.	1.1	13
16	Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. Clinical Pharmacokinetics, 2020, 59, 1171-1183.	1.6	13
17	Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients. British Journal of Clinical Pharmacology, 2019, 85, 1357-1366.	1.1	19
18	Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study. Clinical Pharmacology and Therapeutics, 2019, 106, 585-595.	2.3	19

#	Article	IF	Citations
19	Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2019, 41, 66-74.	1.0	4
20	Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene. Cancer Management and Research, 2018, Volume 10, 4517-4522.	0.9	4
21	Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. Cancer Chemotherapy and Pharmacology, 2018, 82, 361-365.	1.1	9
22	Pharmacogenetics of anti-cancer drugs: State of the art and implementationÂâ€“Ârecommendations of the French National Network of Pharmacogenetics. Therapie, 2017, 72, 205-215.	0.6	28
23	Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx). Therapie, 2017, 72, 185-192.	0.6	38
24	Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study. Clinical Cancer Research, 2017, 23, 7171-7179.	3.2	15
25	Prevention of 5-fluorouracilâ€“induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing. Seminars in Oncology, 2017, 44, 159-160.	0.8	5
26	Dendrogenin A drives LXR to trigger lethal autophagy in cancers. Nature Communications, 2017, 8, 1903.	5.8	84
27	Reply to the letter addressed by Amr A. EL-Arabey â€œDual function of OCT-2 and MATE1 in Cisplatin induced nephrotoxicityâ€• Pharmacological Research, 2017, 119, 494.	3.1	0
28	New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS ONE, 2017, 12, e0175998.	1.1	82
29	Individualization of high dose carboplatin based on therapeutic drug monitoring (TDM) for the treatment of testicular germ cell tumors (TICE protocol): Results of a multicenter phase II study.. Journal of Clinical Oncology, 2017, 35, 4554-4554.	0.8	1
30	Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicentric prospective GETUG trial.. Journal of Clinical Oncology, 2017, 35, 401-401.	0.8	6
31	Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin. Pharmacological Research, 2016, 110, 89-95.	3.1	29
32	Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients. Clinical Pharmacokinetics, 2016, 55, 1145-1157.	1.6	22
33	Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site. Investigational New Drugs, 2016, 34, 41-48.	1.2	22
34	Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. Clinical Pharmacology and Therapeutics, 2016, 99, 235-242.	2.3	33
35	Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiency. International Journal of Colorectal Disease, 2016, 31, 699-701.	1.0	7
36	<scp>UGT</scp>1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundamental and Clinical Pharmacology, 2015, 29, 219-237.	1.0	91

#	Article	IF	Citations
37	Polymorphisms inSLCO1B3andNR1I2as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination. Pharmacogenomics, 2015, 16, 1439-1450.	0.6	14
38	Exhaustive single nucleotide polymorphism (SNP) analysis of DPYD exome in breast cancer patients (pts) receiving capecitabine.. Journal of Clinical Oncology, 2015, 33, 2571-2571.	0.8	4
39	Gene expression profiling on preâ€•and postâ€erlotinib tumors from patients with head and neck squamous cell carcinoma. Head and Neck, 2013, 35, 809-818.	0.9	5
40	Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rareABCC2polymorphism: a case report. Pharmacogenomics, 2013, 14, 1389-1396.	0.6	8
41	123 INVITED Application of Population PK-PD Methods in Oncology. European Journal of Cancer, 2011, 47, S30.	1.3	0
42	Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children. Clinical Cancer Research, 2011, 17, 4862-4871.	3.2	35
43	Thymidylate Synthase Genotype-Directed Neoadjuvant Chemoradiation for Patients With Rectal Adenocarcinoma. Journal of Clinical Oncology, 2011, 29, 875-883.	0.8	58
44	Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. British Journal of Cancer, 2011, 105, 1654-1662.	2.9	49
45	Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro-Oncology, 2011, 13, 109-118.	0.6	137
46	Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis. Pharmacogenomics, 2010, 11, 1751-1756.	0.6	16
47	Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-<scp>D</scp>-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer. Clinical Cancer Research, 2010, 16, 4434-4445.	3.2	27
48	Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. European Journal of Cancer, 2009, 45, 2316-2323.	1.3	76
49	Laparoscopically Assisted Heated Intra-Operative Intraperitoneal Chemotherapy (HIPEC): Technical Aspect and Pharmacokinetics Data. , 2009, , 343-351.		1
50	Pharmacokinetics of Oxaliplatin During Open Versus Laparoscopically Assisted Heated Intraoperative Intraperitoneal Chemotherapy (HIPEC): An Experimental Study. Annals of Surgical Oncology, 2008, 15, 339-344.	0.7	73
51	Increased Tissue Diffusion of Oxaliplatin During Laparoscopically Assisted Versus Open Heated Intraoperative Intraperitoneal Chemotherapy (HIPEC). Annals of Surgical Oncology, 2008, 15, 3623-3624.	0.7	40
52	Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2007, 13, 7086-7092.	3.2	68
53	Investigation of predictive factors of response in patients with squamous-cell carcinoma of the head and neck (SCCHN) given neo-adjuvant erlotinib before surgery, updated results of a single institution experience. Radiotherapy and Oncology, 2007, 82, S31-S32.	0.3	0
54	Genetic diversity of HCV genotype 2 strains in South Western France. Journal of Medical Virology, 2007, 79, 26-34.	2.5	24

#	Article	IF	Citations
55	Contribution of the MDRD Equation and of Cystatin C for Renal Function Estimates in Cancer Patients. Medical Oncology, 2006, 23, 63-74.	1.2	23
56	In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemotherapy and Pharmacology, 2006, 57, 709-718.	1.1	86
57	Ototoxicity of High-Dose Carboplatin. Journal of Clinical Oncology, 2005, 23, 3649-3650.	0.8	14
58	Serum Cystatin C is a Better Marker of Topotecan Clearance than Serum Creatinine. Clinical Cancer Research, 2005, 11, 3038-3044.	3.2	31
59	Cystatin C as a New Covariate to Predict Renal Elimination of Drugs. Clinical Pharmacokinetics, 2005, 44, 1305-1316.	1.6	39
60	Pharmacogenomics: The Influence of Genomic Variation on Drug Response. Current Topics in Medicinal Chemistry, 2004, 4, 1397-1407.	1.0	31